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1. INTRODUCTION 
Understanding of factors related to the clear- 
ance of liposomes from the blood is of central im- 
portance in their use as a drug delivery system [I]. 
For instance, efficient interaction of drug-con- 
taining liposomes with target cells in the intra- 
vascular space or access to extravascular cells is 
likely to be promoted by the carrier’s prolonged 
presence in the circulation. To this end, there has 
been variable success through reduction of vesicle 
size [2], adjustment of surface charge [3], or phos- 
pholipid composition [4,5], the use of phospholip- 
ase-resistant phospholipids [6] and, indirectly, by 
blocking the reticuloendothelial system [3,7,8]. 
However, an important prerequisite for retarded 
liposome clearance is resistance to the detrimental 
effect of blood on bilayer stability 19,101. Recent 
studies have shown that excess cholesterol in cer- 
tain types of liposomes greatly improves bilayer 
stability in the presence of blood and reduces their 
permeability [1 l-161. This has led to the prepara- 
tion of small unilamellar vesicles that, while in the 
circulation, remain relatively intact and retain en- 
trapped solutes quantitatively [11,131. In work with 
such liposomes it was observed [4,5] that rate of 
clearance varied widely according to their phos- 
pholipid component. Here we present evidence 
that liposomal half-life in the circulation is deter- 
mined by the extent to which phospholipids, alone 
or in association with cholesterol, prevent plasma- 
induced bilayer permeability. 
2. MATERIALS AND METHODS 
Sources and grades of PC SM, DSPC, cho- 
lesterol, [JH]PC, [%]SM and CF have been de- 
scribed [5,17]. CF was used without further pu- 
rification since previous work [5] with both the 
purchased (unpurified) and purified CF from the 
same batch showed that the minor proportions of 
impurities in this particular batch (lot C4C) did 
not interfere significantly with the use of the dye as 
a marker of liposomal permeability. The ultravio- 
let and visible absorption spectra of unpurified 
and purified CF (5 PM solution) were practically 
identical [S] and very similar to those obtained by 
others [ 181. 4-APP (95% pure) was purchased from 
Sigma Chemical Company. All other reagents 
were of analytical grade. 
2.1. Preparation of liposomes 
A bbreviatons: PC, egg phosphatidylcholine; SM, 
sphingomyelin; DSPC, distearoyl phosphatidylcholine; 
CF, carboxyfluorescein; 4-APP, 4-aminopyrazolo- 
(3,4d)-pyrimidine. 
Small unilamellar liposomes (30-60 nm average 
diameter) of neutral charge containing quenched 
CF (0.2 M) were prepared from 20 pmol PC, 20 
pm01 SM or combinations of the two phospho- 
lipids (hybrid liposomes; 20 pmol total phospho- 
lipid) mixed with tracer [3H]PC and/or [14C]SM 
and 20 pmol of cholesterol. Sonication [5] was car- 
ried out at 4°C for PC and 37°C for SM and 
hybrid liposomes. The extent of phospholipid in- 
corporation (83.0-94.58 of the amount used) was 
estimated from 3H and/or 14C assays [5,17] in the 
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preparations. In the hybrids, PC content was 23%, 
53% and 77% of total phospholipid. In some ex- 
periments mall unilammellar liposomes were pre- 
pared from DSPC alone (20 pmol) or DSPC (20 
pmol) and equimolar cholesterol with the sonica- 
tion step carried out at about 65°C. They were al- 
lowed to anneal at the same temperature. Forma- 
tion of small unilammellar liposomes (all types) 
and retention of size to the time of their use were 
judged as before [5]. In a few instances, liposomes 
composed of equimolar DSPC and cholesterol 
failed to form [5] and these preparations were dis- 
carded. Others [19] have observed similar difti- 
culties with preparing liposomes from higher melt- 
ing phospholipids. Quenched CF (latency) values 
(95.5-93.3% of total CF) in all liposomal prepara- 
tions immediately before use were estimated [4] 
from 100 (Dye,-Dyef)/Dyel where t and f denote 
total CF measured in the presence of Triton X-100 
(1% final concentration) and free CF respectively. 
CF entrapment values in the preparations were 
0.5-0.8% of total used per ml liposomes. 
2.2. In vitro experiments 
Fresh plasma samples (0.5 ml) from T.O. male 
mice were preheated to 37°C mixed with 0.1 ml 
CF-containing liposomes (0.9- 1.2 pmol phos- 
pholipid and 94-120 pg CF) and incubated at the 
same temperature. At time intervals 10 ,ul of the 
mixtures were assayed [4,5] for CF latency as 
above. Released CF (W of total entrapped) was de- 
rived from differences in CF latency values before 
and after incubation. 
2.3. In vivo experiments 
T.O. male mice weighing 20-25 g were injected 
into the tail vein with 0.2 ml CF-containing lipo- 
somes @H]PC and/or [14C]SM-labelled) (1.8-2.4 
pmol phospholipid, 188-240 pg CF and 9.1 X 104 
-2.0 x 10s dpm 3H and/or 1.0 x 104-3.0 x 104 
dpm 14C). At time intervals 25 ~1 blood plasma 
samples were assayed [4,5] for latent CF. In other 
experiments, T.O. male mice were made lipopro- 
tein deficient [20] by daily intraperitioneal injec- 
tions of 60 mg 4-APP/kg body weight. 4-APP was 
dissolved in 0.5 ml of 0.01 M sodium, phosphate 
adjusted to pH 2 with 1 N HCl before use. In sim- 
ilarly treated control mice 4-APP was omitted from 
the injected solution. 24 h after the last injection, 
4-APP-treated and control mice were tested 1211 
110 
for total cholesterol in blood plasma and then 
given intravenously 0.2 ml CF-containing lipo- 
somes (2.5 pmol phospholipid) composed of equi- 
molar PC and cholesterol. They were bled at time 
intervals and blood plasma samples assayed for 
latent CF as above. Total cholesterol levels 
(mean? SD) in control and 4-APP-treated mice 
were 2.26 + 0.42 (5 mice) and 0.19 f 0.13 mmol/ 
1 plasma (10 mice) respectively. 
3. RESULTS AND DISCUSSION 
Recent work [4,5] with small unilamellar cho- 
lesterol-rich liposomes of varying phospholipid 
composition has revealed a half-life range in mice 
of 0.1-16 h. Half-lives in these experiments [4,5] 
were derived from the clearance patterns of 
quenched CF entrapped in the aqueous phase of 
liposomes and were, therefore, likely to represent 
those of intact vesicles: quenched CF can be mea- 
sured only after the disruption of liposomes with 
Triton X-100 and ensuing dilution of the dye to 
I I I I I I I I I I I II 
0 2 4 6 8 10 12 14 16 18 20 22 24 
Incubation time (hours) 
F&l. The effect of phospholipid composition of lipo- 
somes on their permeability in plasma. In a typical ex- 
periment shown here, small unilamellar liposomes con- 
taining quenched CF and composed of SM (o), 77% SM, 
23% PC (A), 47% SM, 53% PC (o), 23% SM, 77% PC (A) 
and PC (0) were incubated in the presence of mouse 
plasma at 37°C. All liposomal preparations contained 
cholesterol, equimolar to the total phospholipid. CF la- 
tency values at time intervals are % of total CF present. 
For other details see Materials and Methods. 
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Table 1 
In vivo and in vitro behaviour of liposomal CF 
Liposomes 
Half life in vivo (h) 
quenched CFa [ ‘4C]SM b 
CF released Quenched CF 
in vitro removed 
(W of total in vivo 
present)d (W of injected)f 
SM 11.0 10.0 1.0e - 
11% SM, 23% PC 11.0 10.7 1 .oe 2.0 
47% SM, 53% PC 7.0 7.0 6.0 15.9 
23% SM, 71% PC 4.5 3.6 12.3 32.0 
PC 2.1 2.3c 11.5 34.5 
Half-lives estimated from fig.2 
Half-lives estimated from clearance patterns (not shown) of liposomes labelled with 
[ 14C]SM 
Estimated from clearance patterns (not shown) of liposomes labelled with 13H]PC 
Estimated as difference in CF latency before and after incubation with plasma for 
periods of time equivalent to half-lives of quenched CF for the respective prepara- 
tions 
Values were < 2% after 29 h incubation 
Estimated from fig.2 by subtracting quenched CF present in the circulation at times 
equivalent to the (quenched CF-based) half-lives of the respective preparations 
from quenched CF in SM liposomes present at the corresponding periods. For de- 
tails see the text 
Cholesterol-rich small unilamellar liposomes incubated with mouse plasma or injected 
into mice contained quenched CF and were composed of SM only, PC only or of com- 
binations of the two phospholipids in the proportions shown. Molar ratio of total 
phospholipid to cholesterol was 1 .O 
concentrations that will allow it to fluoresce [4]. 
Since such variations in liposome clearance cannot 
be explained on the basis of differences in vesicle 
surface charge or size (all preparations used were 
neutral and of similar average vesicle size [30-60 
nm] (4,5,13]), we have investigated one attribute of 
phospholipids that may influence liposome clear- 
ance namely their varying resistance to removal by 
plasma HDL [16] with bilayer permeability af- 
fected accordingly [5,16]. In the quenched CF-con- 
taining liposomal preparations used in this study, 
the phospholipid component SM was replaced by 
increasing amounts of PC and, as shown in fig.1 
permeability (to CF) in the presence of mouse 
plasma increases accordingly. As expected [4,5,22], 
after intravenous injection of mice with SM lipo- 
somes (tig.2) the rate of clearance of quenched CF 
is slow and remains so upon modest (23%) sub- 
stitution of liposomal SM with PC. However, rate 
of clearance is augmented gradually with 53%, 77% 
and 100% substitution. Half-lives (table 1) as esti- 
mated from clearance patterns of quenched CF 
decreased from 11 (SM and 77% SM, 23% PC lipo- 
somes) to 2.1 h (PC liposomes) with intermediate 
values (7 h and 4.5 h) for the hybrid preparations 
(47% SM, 53% PC and 23% SM, 77% PC) reflecting 
the effect of PC concentration. Similar half-life 
values were obtained when radiolabelled phospho- 
lipids were used as markers of the liposomal lipid 
phase (table 1). 
In spite of this apparently causal relationship 
between liposome permeability in vitro and clear- 
ance in vivo (figs.1 and 2), it could, however, be 
argued that since increasing amounts of PC in SM 
liposomes render these increasingly vulnerable to 
HDL attack [16], corresponding CF leakage from 
the circulating vesicles may be such that the re- 
mainder of entrapped CF is still of high enough 
concentration to self-quench and thus account for 
the reduced vesicle clearance rates. It may there- 
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Fig.2. The effect of phospholipid composition of lipo- 
somes on their clearance from the circulation. Lipo- 
somes as described in fig.1 were injected intravenously 
into mice. Latent CF values (mean&SD; 3-6 animals) 
at time intervals are % of injected latent CF per total 
mouse plasma [4]. For other details see legend to fig.1 
and Materials and Methods. 
fore be that liposomes, regardless of phospholipid 
composition, are removed from the circulation at 
comparable rates and that differences observed are 
artefacts reflecting degrees of CF leakage. This 
possibility, not supported by the similarity in half- 
life values as measured with the quenched CF and 
phospholipid markers (table l), was nonetheless 
examined: according to fig.2, 50% of the quenched 
CF administered in PC liposomes is removed from 
the circulation within 2.1 h (assumed half-life) 
after injection whereas only 18% of quenched CF 
in SM liposomes is removed during the same time. 
If PC and SM liposomes are indeed cleared at the 
same rate, the difference (34.5%; table 1) between 
SM and PC liposomal quenched CF removal dur- 
ing the 2.1 h period should then reflect CF leakage 
from PC liposomes to that extent. As free (leaked) 
CF is removed from the circulation very rapidly 
[13] and its quantitation is therefore difficult if at 
all possible, CF leakage was estimated from fig.1 
where the volume ratio of plasma to liposomes 
simulates that attained in the circulation of mice 
injected as in lig.2. We have already shown 15,131 
that mouse whole blood affects liposomal per- 
meability similarly to or even less than plasma 
and, it is thus probable that CF release caused by 
plasma in vitro is comparable to that occurring in 
the intravascular space in vivo. According to table 
1 and legend there is very little release (< 2%) of 
CF from SM liposomes upon extended (over 29 h) 
incubation with plasma and, assuming that this is 
true in vivo as well, the half-life (11 h) of quenched 
CF in SM liposomes must be a close approxima- 
tion of the clearance rate of the carrier itself. On 
the other hand, after incubation of PC liposomes 
for 2.1 h (the period of time needed for the re- 
moval of 50% of quenched CF from the circula- 
tion) 11.5% of the entrapped CF is released. It 
would thus appear that only a fraction of the dif- 
ference (34.5%) between SM and PC liposomal 
quenched CF removal in vivo at 2.1 h (tentatively 
assumed to represent CF leakage) could be justi- 
lied in these terms. In fact, because of the continu- 
ous removal of liposomes from the circulation, the 
total amount of leaked CF during the 2.1 h period 
must be considerably smaller than the total 
(11.5%) leaked in vitro and has probably no sig- 
nificant influence on the overall quenched CF 
clearance rate. Similar conclusions drawn from ob- 
servations with the hybrid preparations (table 1) 
strongly suggest that small unilamellar liposomes 
are cleared from the blood with half-lives which 
are inversely related to permeability changes in the 
bilayer effected by blood components, presumably 
HDL. This is supported by the finding that in 
lipoprotein deficient mice, half-life of PC lipo- 
somes was increased from 2 h (control mice) to 
4.5 h (see Materials and Methods). 
An alternative explanation for the relationship 
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between liposomal clearance and phospholipid 
component may be that the latter, through struc- 
tural characteristics expressed on the liposomal 
surface, directs vesicle removal from the circula- 
tion, for instance by way of association with op- 
sonins or other proteins and/or recognition by the 
tissues. If so, liposomal preparations sharing the 
same phospholipid component should exhibit sim- 
ilar rates of clearance. This was tested with small 
unilamellar cholesterol-free and cholesterol-rich 
DSPC liposomes. The choice of DSPC enables us 
to use a cholesterol-free preparation that, in con- 
trast to similar preparations made of PC, SM or 
other phospholipids [4,5,16], is reasonably stable 
[4] in the presence of blood and thus suitable for 
clearance studies. Figure 3b shows that half-life 
values for cholesterol-free and cholesterol-rich 
DSPC liposomes in mice (1.3 h and 20 h respec- 
tively) do not support the above proposition and 
are probably too diverse to be attributed to dif- 
ferent phospholipid density on the bilayer. Inter- 
estingly, however, half-lives correspond to partial 
permeability and complete impermeability of the 
respective liposomes in the presence of plasma 
(fig.3a). Further, using the same approach as ear- 
lier to estimate contribution of CF leakage to the 
clearance pattern of the cholesterol-free DSPC 
liposomes, it can be seen (fig.3b) that the dif- 
ference (50%) in quenched CF removal between 
cholesterol-rich and cholesterol-free DSPC lipo- 
somes 1.3 h after injection compares with only 20% 
leakage in vitro for the same period (estimated 
from fig.3a). Again, in view of the continuous 
clearance of liposomes from the circulation, total 
leakage in vivo must have been even less and 
therefore account for only a fraction of removed 
quenched CF. It thus seems likely that the widely 
different half-lives reflect differences in bilayer 
permeability. 
The present results raise a number of questions. 
For instance, assuming that liposomal half-life is 
determined by the extent of plasma-promoted 
bilayer porosity, is a half-life value of 20 h (to our 
knowledge the longest recorded so far) for the 
completely impermeable (to CF) cholesterol-rich 
DSPC liposomes an upper limit? Our experience 
with SM liposomes is that half-life values also de- 
pend on the amount of liposomal lipid injected 
(e.g., 16 h and 10 h for 3 mg and 1 mg injected 
SM) [4,5] and it is conceivable that a dose of DSPC 
80 
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Fig.3. Permeability of DSPC liposomes in mouse plasma 
and clearance from the circulation. Small unilamellar 
liposomes containing quenched CF and composed of 
DSPC (o) or equimolar DSPC and cholesterol (0) were 
incubated in the presence of mouse plasma at 37°C (a) 
or injected intravenously into 4 mice (b). Values at time 
intervals are % latent CF of total CF present or % 
(mean?SD) latent CF of injected latent CF per total 
mouse plasma [4]. For other details see Materials and 
Methods. 
higher than that (1.35 mg) used in fig.3b will ex- 
hibit a greater half-life. Since a half-life upper lim- 
it for stable liposome must exist, presumably to ap- 
proach that shown by a tissue saturation dose, will 
it be different in another animal species (e.g., man) 
when comparable amounts of lipid per kg body 
weight are injected. 7 Furthermore, what is the 
mechanism underlying the removal of intact small 
unilamellar liposomes from the circulation and 
how does it relate to the acceleration of such re- 
moval when bilayers become leaky? Finally, will it 
be possible to apply knowledge acquired with 
113 
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small liposomes to augment he half-lives of larger 
vesicles with higher drug trapping efficiency? An- 
swers to such questions should contribute toward 
the rational application of liposomes in drug deliv- 
ery. 
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